Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): K13

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: K13

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Yabao Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 15, 2015


            Yabao receives exclusive rights to develop and commercialize innovative products targeting PTEN nuclear translocation for the treatment of stroke in China, Taiwan and Hong Kong while Primary Peptides retains rights in all other markets.